Quantinno Capital Management LP Has $2.54 Million Stock Position in LeMaitre Vascular, Inc. $LMAT

Quantinno Capital Management LP increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 357.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 23,298 shares of the medical instruments supplier’s stock after purchasing an additional 18,204 shares during the period. Quantinno Capital Management LP’s holdings in LeMaitre Vascular were worth $2,544,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Sound Income Strategies LLC boosted its stake in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 183 shares during the period. Catalyst Capital Advisors LLC acquired a new stake in LeMaitre Vascular during the 1st quarter valued at $32,000. Geneos Wealth Management Inc. lifted its holdings in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC bought a new position in LeMaitre Vascular during the second quarter worth $47,000. Finally, Quarry LP boosted its position in LeMaitre Vascular by 267.2% during the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after purchasing an additional 529 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: International sales growth and underlying demand were key positives in the second-quarter review. Revenue increased 9.6% year over year to $70.38 million, although growth was constrained by supply issues. LMAT Q2 Deep Dive: International Growth and Supply Constraints Shape Results
• Neutral Sentiment: LeMaitre will hold investor meetings at the Needham Virtual MedTech & Diagnostics 1×1 Conference on August 11. The event could provide management an opportunity to discuss international expansion, supply availability and its outlook, but no new financial guidance was announced. LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference
• Neutral Sentiment: Wells Fargo maintained its Hold rating, signaling limited near-term conviction and a cautious outlook rather than a fresh bullish catalyst. Wells Fargo Sticks to Its Hold Rating for LeMaitre Vascular
• Negative Sentiment: Second-quarter adjusted earnings were $0.74 per share, below the $0.81 consensus estimate, while revenue of $70.38 million missed expectations of $71.47 million. The shortfall triggered a sharp decline and a gap lower in the shares. LeMaitre misses Q2 revenue estimates
• Negative Sentiment: Barrington Research downgraded LMAT to Market Perform, adding to concerns that the stock’s valuation and near-term growth prospects may be less attractive. Barrington Research Downgrades LeMaitre Vascular
• Negative Sentiment: The shares reached a new 12-month low following analyst caution and the earnings disappointment, reinforcing the negative market reaction. LeMaitre Vascular Hits New 12-Month Low

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Citizens Jmp increased their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Finally, Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT opened at $81.45 on Monday. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The stock’s fifty day moving average price is $96.54 and its two-hundred day moving average price is $99.89. LeMaitre Vascular, Inc. has a one year low of $78.65 and a one year high of $118.01. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 28.58, a P/E/G ratio of 2.35 and a beta of 0.53.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The firm had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. During the same period in the prior year, the business posted $0.60 EPS. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be paid a $0.25 dividend. The ex-dividend date is Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular’s payout ratio is 35.09%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.